Hutchison China MediTech Ltd (HCM.OQ)
Wed, Sep 5 2018
LONDON Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.
* Green light shows growing strength of Chinese biotech (Updates with CEO interview, latest shares, background)
LONDON, Sept 5 Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.
- Week In Review: Jiangsu Hansoh To Raise Up To $3 Billion In Hong Kong IPO
- Your Daily Pharma Scoop: Novocure's Mesothelioma Success, Sangamo's Mixed Results, China's First Homegrown Onco Med
- Your Cancer Highlight: Chi-Med Looks To Dominate Colorectal Cancer In China
- Hutchison China MediTech Ltd (HCM) CEO Christian Hogg on Q2 2018 Results - Earnings Call Transcript
- Hutchison China MediTech Ltd. 2018 Q1 - Results - Earnings Call Slides
- 3 Things In Biotech, July 24: Chinese Biotechs Seek A Splash